



Activase® Therapy for Acute Ischemic Stroke Management

Contact Hours: 2.0
First Published: April 12, 2012
Updated: June 11, 2015
Course Expires: June 30, 2018

Copyright © 2012 by RN.com
All Rights Reserved

Reproduction and distribution of these materials is prohibited without an RN.com licensing agreement.

Conflict of Interest and Commercial Support Statement

RN.com strives to present content in a fair and unbiased manner at all times, and has a full and fair disclosure policy that requires course faculty to declare any real or apparent commercial affiliation related to the content of this presentation. Note: Conflict of Interest is defined by ANCC as a situation in which an individual has an opportunity to affect educational content about products or services of a commercial interest with which he/she has a financial relationship.

The author of this course does not have any conflict of interest to declare.

The planners of the educational activity have no conflicts of interest to disclose.

There is no commercial support being used for this course.

Acknowledgments

RN.com acknowledges the valuable contributions of...

...Lindsey Ryan, MSN, RN, CCRN-K, ACNS-BC is a Clinical Content Specialist for RN.com. Lindsey graduated from Point Loma Nazarene University in San Diego, California with both her BSN and MSN. Lindsey's clinical experience ranges from Acute to Critical Care where she has functioned in the roles of frontline staff and CNS. Most recently Lindsey is responsible for leading efforts associated with new knowledge and innovation including interdisciplinary quality initiatives, evidence-based practice projects and clinical research. She identifies areas for development, leads evidence-based implementation efforts, and performs evaluations to ensure positive patient outcomes. Lindsey is a member of the American Association of Critical Care Nurses (AACN) and National Association of Clinical Nurse Specialists (NACNS). She was inducted into the Sigma Theta Tau International Honor Society and holds both Critical Care Nurse (CCRN-K) and Adult CNS certifications.

...Shelley Lynch, MSN, RN, CCRN, author of *Activase Therapy for Acute Ischemic Stroke Management*. Shelley has over 10 years of critical care nursing experience. She completed her Bachelors of Science in Nursing from Hartwick College and her Master's of Science in Nursing with a concentration in education from Grand Canyon University. Shelley has worked in a variety of intensive care units. She worked in trauma intensive care, medical intensive care, surgical intensive care, cardiovascular intensive care, cardiothoracic intensive care, neurosurgical intensive care, and coronary care unit in some of the top hospitals in the United States including: Johns Hopkins Medical Center, Massachusetts General Hospital, New York University Medical Center, Tulane Medical Center, and Beth Israel Deaconess Medical Center. She is the author of RN.com's: *Diabetes Overview, Thrombolytic Therapy for Acute Ischemic Stroke: t- PA/Alteplase, ICP Monitoring, Abdominal Compartment Syndrome, Chest Tube Management, Acute Coronary Syndrome: A Spectrum of Conditions and Emerging Therapies*.

Shelley is a member of the American Association of Critical Care Nurses (AACN) and National League of Nursing (NLN). She was inducted in Sigma Theta Tau International Honor Society. She is currently an Advance Cardiac Life Support (ACLS) and Basic Life Support (BLS) Instructor. She has her Critical Care Registered Nurse (CCRN) and her Trauma Nurse Core Curriculum (TNCC) certifications.

Purpose

The purpose of *Activase® Therapy for Acute Ischemic Stroke Management* is to inform the healthcare provider about stroke and the use of Activase® in treating stroke patients.

As the public becomes more informed about the signs and symptoms of stroke, people are recognizing the signs and symptoms of a stroke earlier and arriving to the hospital where they are quickly being evaluated to receive Activase® for acute ischemic stroke.

With an increased use of this drug, nursing professionals need to develop their knowledge of how to properly care for a patient before, during, and after the administration of Activase®.

Learning Objectives

After successful completion of this course, you will be able to:

1. Identify stroke statistics.
2. Define stroke, state risk factors (both modifiable and non-modifiable), and signs and symptoms of acute ischemic stroke.
3. Define the mechanism of action, patient eligibility, dosage, administration, and adverse side effects of Activase®.
4. Identify the nursing issues to consider when taking care of someone before, during, and after administration of Activase®.

Introduction

The use of Activase® may reduce the debilitating effects of an ischemic stroke. As public awareness of stroke increases, so does the use of Activase®. Activase® is currently the only drug approved by the FDA for treatment of ischemic stroke.

Nurses and Pharmacists in both the emergency department and intensive care unit are most often the involved with the administration of Activase®. Since a stroke can happen at any time, all clinical staff should familiarize themselves with the purpose and use of Activase®.

Note!
Activase® can be referred as Recombinant Tissue Plasminogen Activator, rt-PA, t-PA, Activase®, or alteplase.

This course will focus on the ischemic stroke. For more information on strokes, refer to the RN.com course titled *Stroke Prevention & Recognition*.

Test Yourself

True or False

Activase® can be referred as Recombinant Tissue Plasminogen Activator, rt-PA, t-PA, Activase®, or alteplase. It is the only medication currently approved by the FDA for use with hemorrhagic stroke.

False

Rationale - Activase® is the only medication currently approved by the FDA for use with ISCHEMIC stroke.

Incidence of Stroke

According to the American Heart Association, approximately 795,000 strokes occur in the United States every year. Eighty-seven percent of these strokes are ischemic. In 2007, the overall mortality rate from stroke was 273,000 which makes stroke the third leading cause of death in the United States (Mozaffarian et al., 2015).

From 2001 to 2011, the relative rate of strokes fell by 35.1% and the actual number of stroke deaths declined 21.2%. These vast improvements in outcomes are associated with improved cardiovascular risk factor interventions (Mozaffarian et al., 2015).

Types of Stroke: Ischemic Strokes

When normal blood flow to the brain is hindered, a stroke may occur. Two types of strokes have been identified: ischemic and hemorrhagic.

An ischemic stroke is caused by a narrowing in an artery or a thrombus occluding a blood vessel to or within brain. The obstruction deprives the brain tissue from oxygen and nutrients, resulting in ischemia. Ischemia will lead to cell death if blood flow is not re-established. When cell death occurs, the patient will begin to exhibit certain signs and symptoms depending on the impacted area of the brain.

Types of Stroke: Hemorrhagic Strokes

A hemorrhagic stroke develops when a vessel in the brain leaks or ruptures. The bleeding can occur inside the brain tissue or within the protective layers covering the brain. Hemorrhagic strokes typically require surgical intervention or palliative care and coincide with a higher mortality rate.

Acute Ischemic Stroke

Acute ischemic strokes have devastating effects for both the individual and the healthcare system. According to the National Stroke Association in 2011, the estimated direct and indirect costs of stroke for 2010 are 33.6 billion dollars (Mozaffarian et al., 2015).

Like an acute myocardial infarction, stroke is considered a medical emergency. When a patient arrives at a hospital exhibiting the signs and symptoms of a stroke, most facilities initiate a “stroke code” or a “stroke team” that activates a team of specially trained healthcare professionals to commence a detailed plan of care.

Four minutes without blood and oxygen, brain cell damage begins. Two million brain cells die every minute during a stroke, increasing the risk of permanent brain damage, disability or death (National Stroke Association, 2011).

Causes of Ischemic Stroke

Brain cells die when blood supply is cut off by a clot. In a major stroke the area of damage, also known as the infarction, is surrounded by a wider ring of cells that linger in a dysfunctional state for several hours and will either die or recover. The magnitude of stroke damage depends on how large the artery is, and the size and location of the brain matter it supplies.

Causes of blood clots in ischemic stroke:

- Hardening of the arteries; atherosclerosis
- Atrial fibrillation
- Valvular problems
- Infection of the heart muscle, endocarditis
- Congenital heart defects; patent foramen ovale
- Blood clotting disorders
- Inflammation of blood vessels; vasculitis
- Heart attack

Risk Factors

According to the American Stroke Association (2011), there are 6 major risk factors of stroke. Some risk factors can be changed or modified, while others are part of the genetic make-up, or the environment. Risk factors include:

- Age 55 or older.
- African-American or Hispanic race.
- Women in the later years, men in the younger years.
- Family history.
- Hypertension, heart disease, obesity, high cholesterol, carotid artery disease, drug abuse, smoking, and high alcohol consumption.

Modifiable vs. Non-Modifiable Risks

Non-Modifiable Risks	Modifiable Risks
Increasing age	High blood pressure
Race	Smoking
Gender	Diabetes
Family history	High cholesterol
Prior history of stroke or transient ischemic attack (TIA)	Heart conditions such as atrial fibrillation
	Physical inactivity
	Obesity
	Heavy use of alcohol or street drugs
	Certain medications

(National Stroke Association, 2011)

Educate Patients to Call 9-1-1

Common stroke symptoms include **SUDDEN**:

- Numbness or weakness of the face, arm or leg – especially on one side of the body
- Confusion, trouble speaking or understanding
- Trouble seeing in one or both eyes
- Trouble walking, dizziness, loss of balance or coordination
- Severe headache with no known cause

FAST Test

Use the FAST test for recognizing and responding to stroke symptoms.

Facial Droop:

- Ask the person to smile. Does one side of the face droop?

Arm Drift:

- Ask the person to raise both arms. Does one arm drift downward?

Slurred Speech:

- Ask the person to repeat a simple sentence. Does the speech sound slurred or strange?

Time:

- If you observe any of these signs, it's time to call 9-1-1 or get to the nearest stroke center or hospital.


Use the FAST Test for Recognizing & Responding to Stroke Symptoms



Facial droop



Slurred speech



Arm droop

Genentech. *F.A.S.T. Images*. Originally retrieved March 16, 2012, URL updated 4/8/2015 from: https://www.activase.com/resource/resource_materials.jsp?s=yes#image

Test Yourself

True or False

It is essential that stroke recognition, the causative factor of a stroke be determined, and that treatment begins within a 3 hour time frame.

True


Rationale - Four minutes without blood and oxygen, brain cell damage begins. Two million brain cells die every minute during a stroke, increasing the risk of permanent brain damage, disability or death.

The Golden Hour: Door to Treatment <60 Minutes

The first hour after admission is the most critical time for the stroke patient:

- 0 min: Suspected stroke patient arrives at ED
- <10 min: Complete initial MD evaluation, including patient history and time last known well/symptom onset. Initiate lab work and assess using the National Institute of Health Stroke Scale (NIHSS).
- <15 min: Notify stroke team (including neurologic expertise)
- <25 min: Initiate CT scan
- <45 min: Interpret CT scan and labs, and review patient eligibility for Activase®.
- <60 min: Give Activase® bolus and initiate infusion in eligible patients*

Linear Timeline



Genentech. *Linear Timeline*. Originally retrieved March 16, 2012, URL updated 4/8/2015, from: <http://www.activase.com/iscstroke/golden-hour-acute-ischemic-stroke>

History of t-PA/Activase®

On June 18, 1996, the Food and Drug Administration approved the use of recombinant tissue plasminogen activator (t-PA) or Activase® for acute ischemic stroke, after an article published in the *New England Journal of Medicine* reported that there were improved clinical outcomes following treatment with intravenous Activase® when it was administered within three hours of the onset of ischemic stroke (National Institute of Neurological Disorders and Stroke, 1995).

Prior to Activase®, there was no effective treatment that resulted in more benefit than risk to the patient following an ischemic stroke to dissolve the clot(s) and restore blood flow to the damaged brain tissue.

Activase® acts as a catalyst in the conversion of plasminogen into plasmin. This increased enzymatic activity causes hyperfibrinolysis, which dissolves clots. Tissue plasminogen activator also plays a role in cell migration and tissue remodeling.

Uses of Activase®

According to Genetic (2015), manufacturer of Activase®:

- Intravenous administration within 3 hours of symptom onset is the current FDA-approved thrombolytic therapy for the treatment of patients with acute ischemic stroke.
- Activase® is also approved for treating acute myocardial infarction (AMI), acute pulmonary embolism, and central venous catheter functional restoration (Activase®, 2015).

Indication for Use for Activase®

Activase® is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence and severity of disability.

Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage (Activase®, 2015).

Test Yourself

True or False

Activase® is an antiplatelet medication which will keep future clots from forming.

False

Rationale - Activase® acts as a catalyst in the conversion of plasminogen into plasmin. This increased enzymatic activity causes hyperfibrinolysis, which dissolves clots. Tissue plasminogen activator also plays a role in cell migration and tissue remodeling.

Clinical Presentation in Relation to Stroke Location

Stroke can affect each patient differently, presenting with varying signs and symptoms depending on the location in which the stroke occurs.

If the stroke is located in the left (dominant hemisphere), signs and symptoms may include:

- Left gaze preference
- Right visual field deficit
- Right hemiparesis
- Right hemisensory loss/neglect

If the stroke originates in the right (non-dominant hemisphere), signs and symptoms may include:

- Right gaze preference
- Left visual field deficit
- Left hemiparesis
- Left hemisensory loss/neglect

If the stroke originates in the brainstem, signs and symptoms may include:

- Nausea
- Vomiting
- Diplopia
- Dysconjugate gaze
- Palsy
- Dysarthria and dysphagia
- Vertigo and tinnitus
- Hemiparesis or quadriplegia
- Sensory loss in hemibody or all 4 limbs
- Decreased consciousness
- Hiccups and abnormal respirations

If the Stroke originates in the Cerebellus, signs and symptoms may include:

- Truncal gait ataxia
- Limb ataxia
- Neck stiffness and neck pain
- Hemorrhage
- Focal neurological deficits as in acute ischemic stroke
- Headache especially in subarachnoid hemorrhage
- Light intolerance
- Nausea, vomiting, decreased level of consciousness

(Summers et al., 2009)

Conditions Which Mimic Stroke

There are other conditions that may mimic a stroke in clinical presentation. These conditions include:

- Hypoglycemia
- Seizures
- Complicated migraine
- Hypertensive encephalopathy
- Bell's Palsy

(Adams et al., 2007)

Stroke Assessment Scales

There are several stroke-related assessment scales for measuring level of consciousness, disability, ADL's, mental status, motor function, language, etc. However, the two commonly used stroke-deficit scales include:

- National Institutes of Health Stroke Scale (NIHSS)
- Canadian Neurological Scale

Most Commonly Used Scale: NIHSS

The NIH stroke scale measures several aspects of brain function: consciousness, vision, sensation, movement, speech, and language.

The scale is a serial measure of neurologic deficits on a 42 point scale across 11 categories (see Appendix). The lower the overall score, the better the outcome.

NIHSS Scores

0	No stroke. Typically normal function without neurologic deficit.
1 – 4	Minor stroke
5 – 15	Moderate stroke
15 – 20	Moderate/severe stroke
21 – 42	Severe stroke

The NIHSS & Current Guidelines

Current guidelines allow stroke to be treated with Activase® for a score >4. Summers et al. (2009), stated that patients with a NIHSS score of <10 have a much more favorable outcome at 1 year than patients with a NIHSS score of >20.

Also, the higher the NIHSS score, the higher the risk of intracranial hemorrhage (ICH) after thrombolytic therapy because of the amount of damaged tissue. (NIHSS score >22 having a 17% risk of ICH compared to NIHSS score <10 having a 3% risk of ICH).

Expansion of the Time Window for Treatment of Activase®

In 2009, the American Stroke Association published a journal article about the expansion of the time window for treatment of Activase® from 3 to 4.5 hours:

rtPA should be administered to eligible patients who can be treated in the time period of 3 to 4.5 hours after stroke for patients within Class I Recommendation, Level of Evidence B. The eligibility criteria for treatment in this time period are similar to those for persons treated at earlier time periods, with any one of the following additional exclusion criteria: Patients older than 80 years, those taking oral anticoagulants with an international normalized ratio >1.7, those with a baseline National Institutes of Health Stroke Scale score >25, or those with both a history of stroke and diabetes. Therefore, for the 3-to-4.5– hour window, all patients receiving an oral anticoagulant are excluded regardless of their international normalized ratio (del Zoppo, Saver, Jauch, & Adams, 2009).

More recent research shows that the expanded window may actually cause more patient harm due to an increased risk of bleeding. Activase® indications for use still states 3 hours and we will use this number in the course.

Test Yourself

True or False

Activase® should be given with a 4.5 hour window.

False

Rationale - recent research shows that the expanded window may actually cause more patient harm due to an increased risk of bleeding. Activase® indications for use still states 3 hours.

Safety Risks of Activase®

The most common complication during Activase® therapy is bleeding. Should serious bleeding in a critical location (intracranial, gastrointestinal, retroperitoneal, or pericardial) occur; Activase® therapy should be discontinued immediately.

Death and permanent disability are not uncommonly reported in patients who have experienced stroke (including intracranial bleeding) and other serious bleeding episodes.

Patients with severe neurological deficit (e.g. NIHSS >22) at presentation, have an increased risk of intracranial hemorrhage.

The risks of Activase® therapy may be increased in patients with major early infarction, and should be carefully weighed against the anticipated benefits. This includes patients with major early infarction confirmed by computerized cranial tomography (CT) scan, showing substantial edema, mass effect, or midline shift.

Treatment of patients with minor neurological deficit or with rapidly improving symptoms is not recommended.

Orolingual angioedema has been observed in post-marketing experience in patients treated with

Activase® for AIS. Patients should be monitored during and for several hours after infusion for signs of orolingual angioedema.

(Activase®, 2015)

Did You Know?

According to the American Stroke Association, treating patients early with Activase® reduces disability, which will save money. A cost-benefit analysis estimates that for every patient treated with Activase®, \$4,000 can be saved (American Stroke Association, 2005).


Diagnostic Tests for Suspected Stroke

- Diagnostic tests for suspected stroke may include:
- Non-contrast brain CT or brain magnetic resonance imaging (MRI)
- Blood glucose
- Serum electrolytes/renal function tests
- Electrocardiogram (ECG)
- Cardiac Markers
- Complete CBC
- PT/INR
- aPTT
- Oxygen saturation

(Summers et al., 2009)

Understanding the Importance of Rapid Reperfusion

Rapid reperfusion of the penumbra (the area surrounding the ischemic event) will limit the extent of injury to the brain. Since brain cells are rapidly lost, timing is of the utmost importance in diagnosing and managing strokes.



Genentech. *Penumbra and Reperfusion*.

Retrieved March 16, 2012 from:

<http://www.activase.com/content/image-library/activase-img-impenumbra.jpg>

Test Yourself

True or False

Rapid reperfusion of the penumbra (the area surrounding the ischemic event) will limit the extent of injury to the brain.

True

Rationale - The average stroke patient loses 32,000 brain cells a second, reperfusion offers the potential to limit the amount of ischemic damage.

Mechanisms of Action of Activase®

Activase® is a “clot-buster” that works by binding to the fibrin in a thrombus (clot), converting plasminogen to plasmin, and initiating local fibrinolysis which results in the lysis of the clot and restoration of cerebral blood flow (Activase®, 2015).

The desired end result of re-establishing blood flow is to rescue the ischemic brain tissues, thereby decreasing morbidity and mortality and improving outcomes.

Mechanisms of Action of Activase®

Since Activase® has a high affinity to the fibrin in a clot, it is less likely to convert circulating plasminogen to plasmin, which reduces the potential for systemic bleeding (Activase®, 2015).

The AHA/ASA guidelines give Activase® its strongest recommendation. It is Class 1, Level of Evidence A (Adams et al., 2007).

The American Academy of Neurology (AAN) and the American College of Emergency Physicians also support the use of Activase® if given within the established guidelines of the NINDS.

Eligibility for Treatment of Acute Ischemic Stroke with Activase®

In order to be considered for treatment, the patient must have a clinical diagnosis of stroke and:

- Be of age 18 years old or older.
- Have a measureable neurological deficit.

Doses must be given within the first three hours of onset of symptoms. The timeframe for rescuing compromised, but still viable, brain tissue is brief; the sooner Activase® is administered the better.

Exclusion Criteria of Patient Selection

- Evidence of intracranial hemorrhage on pretreatment CT or MRI
- Only minor or rapidly improving stroke symptoms
- Clinical presentation suggestive of subarachnoid hemorrhage, even with normal CT or MRI
- Active internal bleeding
- Known bleeding diathesis, including but not limited to:
 - Platelet count <100,000/mm
 - Patient received heparin within 48 hours and has an elevated aPTT (greater than upper limit of normal for laboratory)
 - Current use of oral anticoagulants (e.g., warfarin sodium) or recent use with an elevated prothrombin time >15 seconds
- Patient has had major surgery or serious trauma (excluding head trauma) in the previous 14 days
- Within 3 months any intracranial surgery, serious head trauma, or previous stroke
- History of gastrointestinal or urinary tract hemorrhage within 21 days
- Recent arterial puncture at a non-compressible site
- Recent lumbar puncture
- On repeated measurements:
 - Systolic blood pressure greater than 185 mm Hg or diastolic blood pressure greater than 110 mm Hg at the time treatment is to begin
 - Patient requires aggressive treatment to reduce blood pressure to within these limits.
- History of intracranial hemorrhage
- Abnormal blood glucose (<50 or >400 mg/dL)
- Post myocardial infarction pericarditis
- Patient was observed to have seizure at the same time the onset of stroke symptoms were observed
- Known arteriovenous malformation, or aneurysm

(Brain Attack Coalition, 2012; Activase®, 2015)

Side Effects of Activase® Administration

Since there is a 6.4% chance of developing an intracerebral hemorrhage with the use of Activase® (Summers, 2009), the best method for reducing the potential of bleeding is the careful selection of eligible patients, followed by detailed observation and thorough monitoring after administration of the therapy.

In patients with a suspected intracerebral hemorrhage, the Activase® infusion should be immediately discontinued.

Internal bleeding in other systems (gastrointestinal, genitourinary, and respiratory) can occur and may require cessation of treatment depending on severity (Activase®, 2015).

Administration Considerations

The considerations discussed below are a summary of common practices for healthcare professionals to follow when administering Activase®. It is imperative for you to check with your hospital procedures and policies manual for specifics to your facility.

- The administration of Activase® is usually in the emergency department.
- Clinicians should be aware that any patient that receives Activase® will be at an increased risk of bleeding after receiving the medication.
- All invasive procedures should be done before Activase® is administered.

Manage the BP Prior to Activase®

The patient's elevated BP must be controlled (SBP \leq 185 mmHG and DBP \leq 110 mm HG), otherwise Activase® should not be given.

The physician may order an IV Beta Blocker or Nitroglycerin Paste.

Nursing Interventions Prior to Activase® Therapy

Usually facility procedure will indicate that the patient should have two to three large bore (at least an 18 gauge) intravenous catheters and/or a central line. A central line is desirable if the patient has exhibited blood pressure or heart rate problems that may require treatment with IV medications.

If a nasogastric tube will be needed, place the tube before Activase® administration to avoid the potential for bleeding. The emergency room nurse should apply critical thinking and problem solving skills to ensure the patients safety.

Nursing Interventions Prior to Activase® Therapy

The nurse should confirm that the physician has ordered a full work up of blood tests including blood for type and cross-match. Whole blood, packed RBCs, cryoprecipitate, and/or fresh frozen plasma should be available to treat serious bleeding.

The nurse should also insert a urinary catheter. If the catheter is not inserted prior to Activase® administration, it should not be inserted for at least 24 hours, as the risk of hemorrhage is greatest during this time. All invasive procedures should be performed before administering Activase®.

Many facilities require signage at the patient bedside that indicates "*Activase® given*".

Steps for Administration of Activase®

Dosage of Activase®

The recommended total adult dose is 0.9 mg/kg infused over 60 minutes. Maximum doses should not exceed 90 mg.

Recommended administration is to load with 0.09 mg/kg (10% of the 0.9 mg/kg dose) as an I.V. bolus over 1 minute, followed by 0.81 mg/kg (90% of the 0.9 mg/kg dose) as a continuous infusion over 60 minutes.

(Activase®, 2015)

Steps for Administration of Activase®

1. **Check Time Frame:** The indication for use according to the FDA is that Activase® should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage.
2. **Check Dosage:** The FDA-approved dose of Activase® is 0.9 mg/kg (not to exceed 90 mg total dose). 10% of the total dose is administered as an intravenous (IV) bolus dose over 1 minute. The remainder of the dose should be infused over 60 minutes.
3. **Follow Manufacturer's Instructions:** Follow the manufacturer's instructions when reconstituting the 100 mg vial with 100ml of sterile water for injection. Discard excess medication from the 100 mg/100 ml Activase® vial. Then either remove the bolus from the vial or program pump to deliver the bolus at the infusion initiation.
4. **Administer Remaining Dose:** Administer bolus over 1 minute. Administer the remaining 90% of dose over 1 hour.
5. **Saline Flush:** After the completion of medication, a common practice is to spike a 50 ml normal saline bag with the infusion set of the empty Activase® vial. The 50 ml normal saline bag should be infused at the same rate to ensure that the patient received the entire prescribed medication dose.

During Administration of Medication

- During the administration of Activase®, full neurological checks should be done at least every 15 minutes or as needed while the medication is infusing. This includes the full National Institute of Health Stroke Scale (Summers, 2009).
- The nurse should be monitoring blood pressure and pulse every 5-15 minutes and as needed (Adams, 2007).
- The nurse should check for major or minor signs of bleeding (Activase®, 2015).
- Discontinue infusion and obtain an emergency CT scan if the patient develops changes in level of consciousness, deterioration of neurologic status, severe headache, pupillary changes, nausea/vomiting, or acute hypertension (Adams, 2007).

- If any complication occurs, immediately inform attending physician or neurologists.
- The patient will need to be closely monitored for a minimum of one day in an intensive care unit.

Nursing Assessments During & After Activase®

Nursing interventions should include:

- Neurological assessment and vital signs every 15 minutes for the first 2 hours from the start of the Activase® infusion
 - Then every 30 minutes for 6 hours, then every 60 minutes for 16 hours
- BP may be assessed more frequently for hypertension (SBP>180mmHg or DBP >105mmHg)
- Temperature q 4h
- O2 saturation <92%, administer oxygen by NC at 2-3 L/min

Additional Nursing Interventions During & After Activase®

- Monitor patient for major and minor signs of bleeding
- Continuous cardiac monitoring up to 72 hours or more
- Measure intake & output
- Bed rest, HOB >30 degrees if aspiration risk
- IV Fluids at 75-100ml/hr
- No anticoagulants or antiplatelet medications for 24 hours, then start anticoagulant as ordered
- Brain CT or MRI after Activase® therapy
- NPO until dysphagia screening completed

(Summers et al., 2009)

The First 24 Hours After Activase® is Administered

- Monitor for neurologic deterioration: every 15 minutes for the first hour after the infusion is stopped, every 30 minutes for the next 6 hours, and hourly from the eighth post-infusion hour until 24 hours after the infusion was stopped.
- Continue to check for major or minor signs of bleeding.
- Continue to monitor and control blood pressure: every 15 minutes for the first hour after the infusion is stopped, every 30 minutes for the next 6 hours, and hourly from the eighth post-infusion hour until 24 hours after the infusion was stopped.
- Obtain a follow-up CT scan or MRI at 24 hours before starting anticoagulants or antiplatelet.

These guidelines were adopted from the American Association of Neuroscience Nurses (AANN) and American Heart Association (Activase®, 2015).

Other Treatment Options for Acute Ischemic Stroke

Two other options are being reviewed by the FDA that expands the window of opportunity for acute ischemic stroke patients who arrive after the three hour limit. This was previously reviewed (del Zoppo et al., 2009):

1. One option is using intra-arterial Activase® instead of intravenous Activase®. This can be given up to six hours after the onset of a stroke (Summers, 2009).
2. The other option is a mini-corkscrew threaded by catheter up from the groin to the brain to physically retrieve and remove a clot. In August 2004, the FDA approved the use of the Merci Retriever to remove blood clots in the brain. This procedure can also be done within six hours after stroke onset (Becker & Brott, 2005).

Research Update

Research is ongoing, as doctors and scientists try to improve outcomes for stroke survivors.

The National Institute of Neurological Disorders and Stroke (NINDS) conducts stroke research and clinical trials at its laboratories and clinics at the National Institutes of Health (NIH).

Currently, NINDS researchers are studying the mechanisms of stroke risk factors and the process of brain damage that results from stroke. Basic research has also focused on the genetics of stroke and stroke risk factors.

Scientists are working to develop new and better ways to help the brain repair itself to restore important functions. New advances in imaging and rehabilitation have shown that the brain can compensate for function lost as a result of stroke (NINDS, 2012).

Case Study One

A 65-year-old woman, Martha, is shopping at Grocery Mart when she starts to feel dizzy. She shouts out for help saying that she is having trouble seeing. EMS is called and they bring her to the nearest hospital while treating her high blood pressure. The hospital activates the stroke team. Upon evaluation from the physician, she finds out that Martha was admitted in the hospital one month ago for head trauma that resulted in the intracranial hemorrhage. The CT of Martha's head is positive for a bleed.

Is Martha eligible for Activase®?

No! The patient did not meet the criteria for Activase® since the patient had a hemorrhagic stroke and not an ischemic stroke. She also had a history of an intracranial hemorrhage one month ago from a head trauma.

Case Study Two

An 85-year-old male, Joshua, arrives in the ER with family members. His family stated that he was having slurred speech and trouble walking. The stroke team was called. Upon evaluation the stroke team physician found out that the family watched Joshua for a few hours before they brought him into the ER. When asked when symptoms occurred, they had no idea. It was definitely over five hours, but it might have been days ago. The CT of his head showed an ischemic stroke.

Is Joshua eligible for Activase®?

No! Patient has had symptoms of a stroke for over three hours.

Case Study Three

A 55-year-old male, Matthew, was in his executive office when he started having right-sided numbness and weakness. He told his secretary who immediately called EMS. Within twenty minutes, Matthew was in the ER with no movement of his right side. Code stroke was called and within ten minutes, the stroke team physician evaluated him. He had no contraindications for Activase®. Fifteen minutes later he received a CT scan of his head and it was interpreted forty-five minutes later. Head CT was negative for hemorrhagic stroke.

Is Matthew eligible for Activase®?

Yes! Patient has met all the guidelines to receive Activase®. He made it to the emergency room within 3 hours. The patients did not have a hemorrhagic stroke. Matthew was a perfect candidate for Activase®.

Case Study Four

Sam patient, Matthew, after being treated with Ativase® was admitted to the Neurosurgical ICU for further treatment. After four hours he states he is feeling fine and asks that he be allowed to sleep uninterrupted through the night.

Can you allow Matthew to sleep uninterrupted?

No! Neurological deterioration may occur up to 24 hours later, monitoring his neuro status and blood pressure is imperative during the first 24 hours. Continuous monitoring of bleeding at IV sites may indicate signs of bleeding internally. Vigilance is essential to decrease the risk of further injury.

Conclusion

Vigorous scientific investigation has demonstrated that intravenous administration of Activase® is an effective interventional therapy for impending ischemic stroke.

The healthcare provider should understand all the implications of stroke. They should know the risk factors and sign and symptoms.

Currently, the only drug used for acute stroke is Activase®. The healthcare provider should understand who is a candidate for Activase® and what tests and procedures are needed before administration of the thrombolytic. They should understand and follow the strict guidelines.

Healthcare providers should also understand how to properly take care of a patient before, during, and after administration of Activase® in the ER, ICU, and on the medical floors.

Appendix: The NIHSS

For the full version of the NIH Stroke Scale, please click

[http://www.strokecenter.org/wp-content/uploads/2011/08/NIH Stroke Scale.pdf](http://www.strokecenter.org/wp-content/uploads/2011/08/NIH_Stroke_Scale.pdf)

References

At the time this course was constructed all URL's in the reference list were current and accessible. RN.com is committed to providing healthcare professionals with the most up to date information available.

Activase® (2015). Retrieved from <http://www.activase.com/> .

Adams H.P., del Zoppo G., Alberts M.J., Bhatt, D. L., Brass, L., Furlan, A., ... & Wijndicks, E. F. (2007). Guidelines for the early management of adults with ischemic stroke. *Stroke*; 38(5): 1655-1711.

American Stroke Association. (2005). Association publishes blueprint to strengthen stroke care from prevention through recovery. Retrieved from: <http://psychcentral.com/news/archives/2005-02/aha-apb012405.html>.

American Stroke Association. (2011). *Stroke 101*. Retrieved from http://www.stroke.org/site/DocServer/STROKE_101_Fact_Sheet.pdf?docID=4541.

Brain Attack Coalition. (2012). Guidelines. Retrieved from http://www.stroke-site.org/guidelines/tpa_guidelines.html .

Del Zoppo, G.J., Saver, J.L, Jauch, E.C., & Adams, H.P. (2009). Expansion of the time window for treatment of AIS With intravenous tissue plasminogen activator: A science advisory from the American Heart Association/American Stroke Association. *Stroke*, 40: 2945-2948. Retrieved from <http://stroke.ahajournals.org/content/40/8/2945.full.pdf>.

Genentech. F.A.S.T. Images. Retrieved from: https://www.activase.com/resource/resource_materials.jsp?s=yes#image

Genentech. Linear Timeline. Retrieved from: <http://www.activase.com/iscstroke/golden-hour-acute-ischemic-stroke>

Genentech. Penumbra and Reperfusion. Retrieved from: <http://www.activase.com/content/image-library/activase-img-impenumbra.jpg>

Mozaffarian et al., D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., ... & Turner, M. B. (2015). Executive summary: Heart disease and stroke statistics-2015 update a report from the American Heart Association. *Circulation*, 131(4), 434-441.

National Institute of Neurological Disorders and Stroke. (2011). *Stroke: Hope through research*. Retrieved from http://www.ninds.nih.gov/disorders/stroke/detail_stroke.htm#177111105.

National Institute of Neurological Disorders and Stroke. (1995) rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med*, 333: 1581-1587.

Summers, D., Leonard, A., Wentworth, D., Saver, F. L., Simpson, J., Spilker, J. A., ...& Mitchell, P. H. (2009). Comprehensive overview of nursing and interdisciplinary care of the acute ischemic stroke patient: A scientific statement from the American Heart Institute. *Stroke*, 40: 2911-2944.

Disclaimer

This publication is intended solely for the educational use of healthcare professionals taking this course, for credit, from RN.com, in accordance with RN.com terms of use. It is designed to assist healthcare professionals, including nurses, in addressing many issues associated with healthcare. The guidance provided in this publication is general in nature, and is not designed to address any specific situation. As always, in assessing and responding to specific patient care situations, healthcare professionals must use their judgment, as well as follow the policies of their organization and any applicable law. This publication in no way absolves facilities of their responsibility for the appropriate orientation of healthcare professionals. Healthcare organizations using this publication as a part of their own orientation processes should review the contents of this publication to ensure accuracy and compliance before using this publication. Healthcare providers, hospitals and facilities that use this publication agree to defend and indemnify, and shall hold RN.com, including its parent(s), subsidiaries, affiliates, officers/directors, and employees from liability resulting from the use of this publication. The contents of this publication may not be reproduced without written permission from RN.com

Participants are advised that the accredited status of RN.com does not imply endorsement by the provider or ANCC of any products/therapeutics mentioned in this course. The information in the course is for educational purposes only. There is no “off label” usage of drugs or products discussed in this course.

You may find that both generic and trade names are used in courses produced by RN.com. The use of trade names does not indicate any preference of one trade named agent or company over another. Trade names are provided to enhance recognition of agents described in the course.

Note: All dosages given are for adults unless otherwise stated. The information on medications contained in this course is not meant to be prescriptive or all-encompassing. You are encouraged to consult with physicians and pharmacists about all medication issues for your patients.